Glucagon Gene: In-depth Analysis of Its Role in Peptide Product Composition
Abstract: The glucagon gene encodes proglucagon, a precursor for key peptide products including glucagon, GLP-1, and GLP-2. This in-depth analysis examines its role in peptide composition, comparing brand products (e.g., Novo Nordisk vs. generic suppliers) on purity (>98% vs. 95%), stability, and cost. Market trends show a 12.4% CAGR (2024–2030) driven by diabetes and obesity therapies. Technical advantages include targeted glycemic control; limitations involve short half-life requiring formulation innovations. Product certifications (GMP, USP) and factory audits (FDA, EU) are critical for quality. Logistics require cold-chain (-20°C) to maintain bioactivity. Industry data highlights glucagon’s expanding use in diagnostics and weight management, with brand differentiation via delivery systems (e.g., nasal vs. injectable). Selection criteria prioritize purity, regulatory compliance, and supplier transparency.